biostudies-literatureSlominski RMBLRD VANIAID NIH HHSNIMHD NIH HHSVANIAMS NIH HHSNIH HHS885-890https://www.ebi.ac.uk/biostudies/studies/S-EPMC7436895biostudies-literatureUnknown29(9)The negative outcomes of COVID-19 diseases respiratory distress (ARDS) and the damage to other organs are secondary to a "cytokine storm" and to the attendant oxidative stress. Active hydroxyl forms of vitamin D are anti-inflammatory, induce antioxidative responses, and stimulate innate immunity against infectious agents. These properties are shared by calcitriol and the CYP11A1-generated non-calcemic hydroxyderivatives. They inhibit the production of pro-inflammatory cytokines, downregulate NF-κΒ, show inverse agonism on RORγ and counteract oxidative stress through the activation of NRF-2. Therefore, a direct delivery of hydroxyderivatives of vitamin D deserves consideration in the treatment of COVID-19 or ARDS of different aetiology. We also recommend treatment of COVID-19 patients with Experimental dermatologyCOVID-19 and Vitamin D: A lesson from the skin.PMC7436895R01 AR073004R01 AR071189R21 AI1492671R21AI149267-01A11R01AR073004R21 MD0153191I01BX004293-01A1I01 BX004293R01AR071189Stefan JSlominski ATRaman CAthar MJetten AMHolick MFSlominski RMfalseCOVID-19 and Vitamin D: A lesson from the skin.The negative outcomes of COVID-19 diseases respiratory distress (ARDS) and the damage to other organs are secondary to a "cytokine storm" and to the attendant oxidative stress. Active hydroxyl forms of vitamin D are anti-inflammatory, induce antioxidative responses, and stimulate innate immunity against infectious agents. These properties are shared by calcitriol and the CYP11A1-generated non-calcemic hydroxyderivatives. They inhibit the production of pro-inflammatory cytokines, downregulate NF-κΒ, show inverse agonism on RORγ and counteract oxidative stress through the activation of NRF-2. Therefore, a direct delivery of hydroxyderivatives of vitamin D deserves consideration in the treatment of COVID-19 or ARDS of different aetiology. We also recommend treatment of COVID-19 patients with 2020-01-01T00:00:00Z2020 Sep2026-05-02T22:18:18.034Z2022-07-19T07:47:22.391ZS-EPMC74368953277921310.1111/exd.14170